Startups
1985
PALO BIOFARMA SL
Dirección
Carrer d'Ernest Lluch 32, 08302 Mataró, España
Datos financieros
Propiedad de CERCA
Barcelona, Spain
1992
Hospital del Mar Research Institute (HMRIB)
Contacto del Centro CERCA
IÁ
Ismael Ávila
Hospital del Mar Research Institute (HMRIB)Estado
Estado de la empresaEstado actual de la empresa
Área DeepTech
Descripción
Descripción
La Visión de Palobiofarma es descubrir el primer fármaco comercializado basado en un modulador selectivo de los receptores de adenosina.Palobiofarma centró los recursos internos en áreas donde radica la experiencia del equipo directivo: Diseño virtual de fármacos Química Medicinal Farmacología in Vitro de la adenosina Caracterización fisicoquímica de los compuestos Propiedad Intelectual El resto de actividades necesarias para la caracterización completa del compuesto y la nominación de un candidato a desarrollo, como los ensayos de farmacología y toxicología, se llevan a cabo a través de colaboraciones con diversas empresas (CROs), Centros de Investigación y Universidades.
Descripción del producto
PBF-677 - Potent and selective, GI-restricted adenosine A3 receptor antagonist as first in class oral treatment for IBD. Phase I in healthy volunteers has been completed and a POC trial in ulcerative colitis patients is in progress.
PBF-1650 - Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of autoimmune diseases like psoriasis and NASH. Phase I studies in healthy volunteers are in progress.
PBF-999 - Dual Adenosine A2a receptor antagonist / Phosphodiesterase 10 (PDE-10) inhibitor for the treatment of tumors, especially for “cold tumors”, as for example colon cancers. A Phase I dose escalation study in patients with biopsiable solid tumors is in progress
PBF-1129 - Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers has been completed with the compound and a Phase I dose escalation study in lung cancer patients is in progress.
PBF-680 - Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD. The compound has demonstrated excellent safety, tolerability, and pharmacokinetic profile in humans following administration of single and multiple ascending. A POC trial in asthmatics has been completed with positive results. Phase II clinical in mild to moderate asthmatics are in progress.
PBF-509 - Potent, non-furan containing adenosine A2A receptor antagonist for as novel checkpoint inhibitor for the treatment of solid tumors. The compound has been out-licensed to Novartis through an agreement signed in 2015 and is facing Phase II clinical trials in nine different tumor types.
PBF-1650 - Potent and selective, orally bioavailable adenosine A3 receptor antagonist for the treatment of autoimmune diseases like psoriasis and NASH. Phase I studies in healthy volunteers are in progress.
PBF-999 - Dual Adenosine A2a receptor antagonist / Phosphodiesterase 10 (PDE-10) inhibitor for the treatment of tumors, especially for “cold tumors”, as for example colon cancers. A Phase I dose escalation study in patients with biopsiable solid tumors is in progress
PBF-1129 - Potent and selective adenosine A2b receptor antagonist as first in class oral treatment for Idiopathic Pulmonary Fibrosis and lung cancer. Phase I clinical trials in healthy volunteers has been completed with the compound and a Phase I dose escalation study in lung cancer patients is in progress.
PBF-680 - Potent, non-BBB permeable, adenosine A1 receptor antagonist as a first in class oral treatment of respiratory diseases as asthma and COPD. The compound has demonstrated excellent safety, tolerability, and pharmacokinetic profile in humans following administration of single and multiple ascending. A POC trial in asthmatics has been completed with positive results. Phase II clinical in mild to moderate asthmatics are in progress.
PBF-509 - Potent, non-furan containing adenosine A2A receptor antagonist for as novel checkpoint inhibitor for the treatment of solid tumors. The compound has been out-licensed to Novartis through an agreement signed in 2015 and is facing Phase II clinical trials in nine different tumor types.